1
Clinical Trials associated with CT101aA Phase 1 Study of Evaluating Preliminary Safety and Efficacy of CT101a in the Treatment of Relapsed or Refractory (r/r) AML Patients
This is a single-arm, open-label, non-randomized, multiple-dose, phase 1 dose escalation study evaluating the safety, efficacy and PK of CT101a in patients with relapsed/refractory acute myeloid leukemia.
Primary Objective:
To evaluate the safety and tolerability of CT101a and estimate the MTD in Chinese patients.
Secondary Objective:
To determine the preliminary efficacy of CT101a in the treatment of r/r AML by IWG response rate; To determine the duration of response, time to progression, disease-free survival, and overall survival of AML patients treated with CT101a.
Exploratory Objective:
To investigate and analyze the correlation between the donor KIR gene and the efficacy in the subject.
To explore the feasibility and safety of multiple doses of CT101a in the treatment of r/r AML.
To detect blood samples and bone marrow samples before and after CT101a infusion by single cell sequencing method, and to perform difference analysis.
100 Clinical Results associated with CT101a
100 Translational Medicine associated with CT101a
100 Patents (Medical) associated with CT101a
100 Deals associated with CT101a